Innate shows Bicycle the path for Nectin-4
While Bicycle clings to the hope of first-line treatment, Innate eyes a post-Padcev fast track.
The month ahead: February’s upcoming events
Approval decisions await Ono and SpringWorks, while key data approach for Pfizer and Arvinas’s SERD.
FDA red and green lights: January 2025
AstraZeneca bags three of the month’s four oncology approvals.
Atara still can't get across the US finish line
Just when investors thought things couldn't get any worse, they do.
Zai Lab looks towards an accelerated pathway
The company believes that its DLL3-targeting ADC could be fast-tracked despite the presence of Imdelltra.
